Sunil Mathur
Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo
Mathur, Sunil; Turnbull, Agnes; Akaev, Iolia; Stevens, Craig; Agrawal, Neerja; Chopra, Mridula; Mincher, David
Authors
Agnes Turnbull Ag.Turnbull@napier.ac.uk
Teaching Student Support Tutor
Iolia Akaev
Dr Craig Stevens C.Stevens@napier.ac.uk
Associate Professor
Neerja Agrawal
Mridula Chopra
Dr David Mincher D.Mincher@napier.ac.uk
Senior Lecturer
Abstract
The lysosomal endoprotease legumain (asparaginyl endoprotease) has been proposed as a putative biomarker in prostate tumours, in which the enzyme is markedly overexpressed. Overexpression, coupled with highly selective specificity for cleavage of substrates at the C-terminus of asparagine (Asn) residues, make legumain an attractive biochemical target for potential diagnosis, prognosis and treatment. We report the design, synthesis, characterisation and preliminary evaluation of a new rhodamine-B (Rho-B)-labelled legumain peptide substrate probe 5 [Rho-Pro-Ala-Asn-PEG-AQ(4-OH)] and its selective targeting to lysosomes in PC3 prostate cancer cells. Probe 5 was efficiently activated by recombinant human legumain to afford the high quantum yield reporter fluorophore tripeptide 4b (Rho-Pro-Ala-Asn-OH) with concomitant release of intense fluorescence. Furthermore, probe 5 was activated upon incubation with homogenates derived from fresh-frozen tissue material of prostatectomy specimens. Probe 5 represents a new viable biochemical tool for probing the activity of legumain with the potential to be used in ex vivo diagnostics in the cancer pathology laboratory.
Citation
Mathur, S., Turnbull, A., Akaev, I., Stevens, C., Agrawal, N., Chopra, M., & Mincher, D. (2020). Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis ex vivo. International Journal of Peptide Research and Therapeutics, 26, 1965-1980. https://doi.org/10.1007/s10989-019-09994-1
Journal Article Type | Article |
---|---|
Acceptance Date | Dec 9, 2019 |
Online Publication Date | Dec 17, 2019 |
Publication Date | 2020-12 |
Deposit Date | Dec 20, 2019 |
Publicly Available Date | Dec 20, 2019 |
Print ISSN | 1573-3149 |
Electronic ISSN | 1573-3904 |
Publisher | Springer |
Peer Reviewed | Peer Reviewed |
Volume | 26 |
Pages | 1965-1980 |
DOI | https://doi.org/10.1007/s10989-019-09994-1 |
Keywords | Prostate cancer, Biomarker, Legumain, Diagnosis, Synthesis |
Public URL | http://researchrepository.napier.ac.uk/Output/2386672 |
Files
Design of a New Peptide Substrate Probe of the Putative Biomarker Legumain with Potential Application in Prostate Cancer Diagnosis Ex Vivo
(1.4 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
Copyright Statement
This article is licensed under a Creative Commons Attribution 4.0 International License.
You might also like
Anthracene derivatives as anti-cancer agents.
(2004)
Patent
Design and evaluation of novel theranostic fluorogenic dual probe-prodrug in cancer
(2016)
Presentation / Conference Contribution
Development of mitochondria- and protease-specific prodrugs in the potential treatment of parasitic helminth infections
(2016)
Presentation / Conference Contribution
Downloadable Citations
About Edinburgh Napier Research Repository
Administrator e-mail: repository@napier.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search